SA

Shah Afjal Khan

Active Director Director DIN 08678919
DIN 08678919 First appointment Jan 2020 Primary industry Business Services
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Shah Afjal Khan

Data last updated:

Shah Afjal Khan is a Director at Cliniva Biotech Private Limited (since 2020). The company operates in Business Services.

DIN 08678919
Primary Designation Director
Industry Business Services
First Appointment 24 Jan 2020
Oldest Company Age 6 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Cliniva Biotech Private Limited U74999BR2020PTC045153
Director24 Jan 20202020Active

Board colleagues of Shah Afjal Khan

NameDINCompanyDesignation
Md Sanu08678920Cliniva Biotech Private LimitedDirector
Noori Gani08678921Cliniva Biotech Private LimitedDirector

Directorship timeline

Open interactive timeline →
Cliniva Biotech Private Limited
Premium access

Shareholding and investment profile for Shah Afjal Khan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shah Afjal Khan

Shah Afjal Khan currently holds 1 directorship: Cliniva Biotech Private Limited (Director, since 24 Jan 2020).

Shah Afjal Khan was first appointed on 24 Jan 2020 as Director at Cliniva Biotech Private Limited.

The current boards of Shah Afjal Khan's companies include Md Sanu (Cliniva Biotech Private Limited), Noori Gani (Cliniva Biotech Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available